Catalyst Pharmaceuticals (CPRX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-13.91M
Depreciation	31.44K
Stock-based compensation	1.35M
Decrease in government grant receivable
Decrease (increase) in prepaid expenses and deposits	1.19M
Increase in accounts payable	-738.8K
Increase (decrease) in accrued expenses and other liabilities	-697.4K
Net cash used in operating activities
Capital expenditures	-88.93K
Purchase of certificate of deposit
Net cash used in investing activities
Proceeds from issuance of common stock, net
Proceeds from issuance of preferred stock, net
Payment of employee withholding tax related to RSUs	-11.27K
Net cash provided by financing activities
Net (decrease) increase in cash	-10.6M
Cash and cash equivalents at beginning of period	28.24M
Cash and cash equivalents at end of period	17.64M
Non-cash incentive received from lessor	0

Entities mentioned with CPRX

View All Entities